SciSparc Announces Major Breakthrough with Alzheimer’s Treatment
SciSparc Ltd (Nasdaq: SPRC) has announced positive topline results from its investigator-initiated Phase IIa trial evaluating its proprietary SCI-110 treatment for Alzheimer’s agitation. The trial results indicated that SCI-110 provided a safe and effective solution for alleviating agitation in elderly Alzheimer’s disease (AD) patients. Patients treated with SCI-110 were free of delirium, oversedation, hypotension, or falls, demonstrating its potential safety and suitability for elderly patients. The company’s share price rose nearly 50% following the news.
Dr. Adi Zuloff- Shani, Chief Technologies Officer of SciSparc, said, “We are thrilled with these outcomes, as they signify a monumental potential in enhancing the lives of AD patients. Our commitment to pioneering innovative treatments with a global impact has never been clearer.”
Highlights
SciSparc’s open-label Phase IIa trial evaluated the safety, tolerability and effectiveness of SCI-110 in 18 AD patients with agitation.
The results not only met primary endpoints regarding tolerability and adverse events but also demonstrated SCI-110’s potential to alleviate agitation without side effects.
SCI-110 is a unique combination of FDA-Approved Dronabinol and the Company’s proprietary CannAmide™ formulation.
Agitation is a devastating symptom of AD, affecting nearly all patients as the disease progresses, and imposing tremendous suffering and caregiving burdens. Existing treatments, including off-label medications, have questionable efficacy and come with notable side effects.
About SciSparc
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp-based products on the Amazon.com marketplace.
